Kunisada Toshiyuki, Hasei Joe, Fujiwara Tomohiro, Nakata Eiji, Yokoo Suguru, Demiya Koji, Ozaki Toshifumi
Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1, Shikata-cho, Okayama, 700-8558, Japan.
Department of Medical Materials for Musculoskeletal Reconstruction, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1, Shikata-cho, Okayama, 700-8558, Japan.
Sci Rep. 2020 Dec 9;10(1):21578. doi: 10.1038/s41598-020-78409-9.
Unidirectional porous hydroxyapatite (UDPHAp) was developed as an excellent scaffold with unidirectional pores oriented in the horizontal direction with interpore connections. The purpose of this study was to assess radiographic changes and clinical outcomes and complications following UDPHAp implantation to treat benign bone tumors. We retrospectively analyzed 44 patients treated with intralesional resection and UDPHAp implantation for benign bone tumors between 2010 and 2015. Clinical and radiographic findings were evaluated postoperatively at regular follow-up visits. The mean follow-up was 49 months. Radiographic changes were classified into five stages based on bone formation in the implanted UDPHAp according to Tamai's classification. All patients showed excellent bone formation inside and around implanted UDPHAp. Absorption of UDPHAp and bone marrow cavity remodeling was identified in 20 patients at a mean of 17 months postoperatively, and was significantly more common in young patients. Preoperative cortical thinning was completely regenerated in 26 of 31 patients on average 10 months after surgery. There were no cases of delayed wound healing, postoperative infection, or allergic reaction related to implanted UDPHAp. UDPHAp is a useful bone-filling substitute for treating benign bone tumor, and the use of this material has a low complication rate.
单向多孔羟基磷灰石（UDPHAp）被开发为一种出色的支架，其具有在水平方向上定向且孔间相互连通的单向孔隙。本研究的目的是评估UDPHAp植入治疗良性骨肿瘤后的影像学变化、临床结果及并发症。我们回顾性分析了2010年至2015年间接受瘤内切除及UDPHAp植入治疗良性骨肿瘤的44例患者。在术后定期随访时评估临床和影像学表现。平均随访时间为49个月。根据Tamai分类法，根据植入的UDPHAp中的骨形成情况将影像学变化分为五个阶段。所有患者在植入的UDPHAp内部及周围均显示出良好的骨形成。20例患者在术后平均17个月时出现UDPHAp吸收及骨髓腔重塑，且在年轻患者中更为常见。31例患者中有26例术前皮质变薄在术后平均10个月时完全再生。未出现与植入UDPHAp相关的伤口愈合延迟、术后感染或过敏反应病例。UDPHAp是治疗良性骨肿瘤的一种有用的骨填充替代物，使用该材料的并发症发生率较低。
